WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?

With its latest trial win, Eli Lilly and its Chinese partner Innovent Biologics are eyeing an all-important front-line non-small cell lung cancer approval in China for their PD-1 checkpoint inhibitor, Tyvyt. But competition with Merck & Co.’s formidable Keytruda lies ahead.